<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Epidemiology, clinical presentation, and diagnosis of bone metastasis in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Epidemiology, clinical presentation, and diagnosis of bone metastasis in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Epidemiology, clinical presentation, and diagnosis of bone metastasis in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael H Yu, MD, ScM
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sarah E Hoffe, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Reed E Drews, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Janet Abrahm, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Raphael E Pollock, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Arvin Kheterpal, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Melinda Yushak, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 21, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H13163455">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bone metastases are a common manifestation of distant relapse from many types of solid cancers, especially those arising in the lung, breast, and prostate [
         <a href="#rid1">
          1
         </a>
         ]. Bone is the third most common organ affected by metastases, after the lung and liver. For hematologic malignancies, bone involvement can also be extensive in patients with multiple myeloma, and bone may be a primary or secondary site of disease involvement in patients with lymphoma. (See
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Bone metastases represent a prominent source of morbidity [
         <a href="#rid2">
          2,3
         </a>
         ]. Skeletal-related events (SREs) that are due to bone metastases can include pain, pathologic fracture, hypercalcemia, and spinal cord compression. Across a wide variety of tumors involving bone, the frequency of SREs can be reduced through the use of osteoclast inhibitors, such as bisphosphonates or
         <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">
          denosumab
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/2804.html" rel="external">
          "Overview of cancer pain syndromes", section on 'Multifocal bone pain'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">
          "Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/842.html" rel="external">
          "Hypercalcemia of malignancy: Mechanisms", section on 'Osteolytic metastases'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2819.html" rel="external">
          "Clinical features and diagnosis of neoplastic epidural spinal cord compression"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2801.html" rel="external">
          "Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6663.html" rel="external">
          "Multiple myeloma: The use of osteoclast inhibitors"
         </a>
         .)
        </p>
        <p>
         The incidence, distribution, clinical presentation, and diagnosis of adult patients with bone metastases is presented here. An overview of therapeutic options is provided separately, as are most detailed discussions of the mechanisms of bone metastases. Specific issues related to bone metastases in patients with prostate cancer, multiple myeloma, and primary lymphoma of bone (PLB) are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/115410.html" rel="external">
          "Overview of therapeutic approaches for adult patients with bone metastasis from solid tumors"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2828.html" rel="external">
          "Mechanisms of bone metastases"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2815.html" rel="external">
          "Cancer pain management: Role of adjuvant analgesics (coanalgesics)", section on 'Patients with bone pain'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2798.html" rel="external">
          "Cancer pain management: Use of acetaminophen and nonsteroidal anti-inflammatory drugs", section on 'Efficacy'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2805.html" rel="external">
          "Radiation therapy for the management of painful bone metastases", section on 'External beam radiation therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2805.html" rel="external">
          "Radiation therapy for the management of painful bone metastases", section on 'Bone-targeted radioisotopes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83808.html" rel="external">
          "Image-guided ablation of skeletal metastases"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">
          "Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2801.html" rel="external">
          "Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6663.html" rel="external">
          "Multiple myeloma: The use of osteoclast inhibitors"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6948.html" rel="external">
          "Bone metastases in advanced prostate cancer: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17128.html" rel="external">
          "Bone metastases in advanced prostate cancer: Management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Bone pain'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13163461">
         <span class="h1">
          MECHANISMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The exact mechanism of bone metastasis is not fully understood. Multiple pathways have been implicated in the development of bone metastases. Bone undergoes constant remodeling, maintaining a dynamic balance between osteoclastic (resorptive) and osteoblastic (bone-forming) activity. As a metastatic focus (which is more often in the marrow than in cortical bone (see
         <a class="local">
          'Distribution'
         </a>
         below)) enlarges, osteoclastic and osteoblastic reactive changes occur simultaneously:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Once cancer cells are established in the bone, interaction of the tumor cells, osteoblasts, and osteoclasts create a vicious cycle that increases bone turnover, leading to osteolytic destruction while promoting the survival of malignant tumor cells  (
         <a class="graphic graphic_figure graphicRef95886" href="/z/d/graphic/95886.html" rel="external">
          figure 1
         </a>
         ). Activated osteoblasts stimulate production of the receptor activator of nuclear factor kappa B (RANK) ligand (RANKL), which interacts with RANK receptors to activate osteoclasts. These activated osteoclasts then resorb bone, which results in osteolysis with concomitant release of growth factors to induce tumor growth. The osteoblastic component of a lytic metastasis represents the reaction of normal bone to the metastatic process. (See
         <a class="medical medical_review" href="/z/d/html/2828.html" rel="external">
          "Mechanisms of bone metastases", section on 'Osteoblasts'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The mechanism underlying predominantly osteoblastic metastasis is not well understood, but tumor factors, such as tumor-derived peptide endothelin-1 (ET-1), may be implicated in some solid tumors, such as prostate cancer [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2828.html" rel="external">
          "Mechanisms of bone metastases", section on 'Osteoblasts'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3607596988">
         <span class="h2">
          Osteolytic versus osteoblastic bone metastases
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanisms underlying bone metastases are reflected in the radiographic appearance; when bone-forming processes predominate, the lesions appear blastic, while if resorptive processes are dominant, the metastases appear lytic. Tumor type influences the predominance of osteolytic versus osteoblastic metastases  (
         <a class="graphic graphic_table graphicRef54124" href="/z/d/graphic/54124.html" rel="external">
          table 1
         </a>
         ). Osteolytic metastases are more likely to cause symptomatic complications, such as pathologic fractures, and thus, are more likely to manifest themselves earlier than osteoblastic metastases.
        </p>
        <p class="headingAnchor" id="H2002100094">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bone is one of the most common sites of distant metastases from cancer [
         <a href="#rid2">
          2,5,6
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At postmortem, 70 to 90 percent of patients with breast or prostate cancer have some form of skeletal metastases [
         <a href="#rid7">
          7,8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among solid cancers, breast, prostate, lung, thyroid, and kidney cancer account for 80 percent of all skeletal metastases. However, many other primary malignant tumors can spread to bone, including, but not limited to, melanoma, lymphoma, sarcoma, and gastrointestinal malignancies, as well as uterine carcinomas.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skeletal lytic lesions are present at the time of diagnosis in approximately 60 percent of patients with multiple myeloma. Myeloma lesions are rarely sclerotic; when they are, they are often associated with the POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal spike, skin changes) [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6662.html" rel="external">
          "POEMS syndrome", section on 'Osteosclerotic bone lesions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Imaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Due to the prevalence of bone metastases, ongoing improvements in systemic therapy that prolong the lives of patients with metastatic disease [
         <a href="#rid10">
          10,11
         </a>
         ], and the fact that metastatic bone disease (especially fracture) is a major contributor to the deterioration in quality of life in patients with cancer [
         <a href="#rid12">
          12,13
         </a>
         ], bone metastases represent a significant healthcare burden that is expected to increase in the coming years as an aging population develops malignancy [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13163467">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many metastatic bone lesions cause few or no symptoms and are diagnosed incidentally during the initial staging evaluation of the index cancer. In general, outside of a clinical trial setting, there is usually no reason to scan for bone metastases in the absence of symptoms unless routine laboratory studies indicate an elevated alkaline phosphatase or an elevated calcium level. In those cases, further evaluation with a fractionated alkaline phosphatase test (liver versus bone) would be indicated and could lead to further diagnostic imaging. Hypercalcemia might prompt further diagnostic evaluation as well. Hypercalcemia occurs more commonly in patients with osteolytic than with osteoblastic metastases. (See
         <a class="medical medical_review" href="/z/d/html/3576.html" rel="external">
          "Approach to the patient with abnormal liver biochemical and function tests", section on 'Elevated alkaline phosphatase'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/836.html" rel="external">
          "Diagnostic approach to hypercalcemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/842.html" rel="external">
          "Hypercalcemia of malignancy: Mechanisms"
         </a>
         .)
        </p>
        <p>
         For symptomatic patients, pain is the most common symptom, and many patients with bone metastasis experience significant pain at some point in their disease course.
        </p>
        <p>
         The characteristics and intensity of the pain may vary depending on the presence or absence of neuromas as part of tumor-induced bone remodeling, endosteal nerve compression by tumor, nerve injury from extension of the bone metastasis out of the bone, and location of the metastasis within the bone. The character of the pain may be somatic (ie, achy, sharp, well-localized), neuropathic (ie, burning, shooting, radiating), or both. It may be constant or exacerbated by movement of the joint or involved bone (so-called "incident" pain). Incident pain is particularly hard to treat in these patients because it comes on and remits suddenly and may be very severe. Neuropathic pain is often worse at night. A complication, such as invasion of adjacent structures, usually results in constant, progressively worsening pain. If the structure is the epidural space, producing compression of the spinal cord, the pain is likely to be worse at night and very intense. Sudden severe pain may be caused by a pathologic fracture, and prompt evaluation, especially in patients with a history of cancer, is necessary. Pathologic fractures are more likely to occur in osteolytic as compared with osteoblastic metastases. (See
         <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">
          "Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p>
         In the clinical setting, pain intensity is often measured simply by using a verbal rating scale (eg, "mild," "moderate," or "severe") or a numeric scale (eg, "how severe has your pain been, on average, during the past week, on a scale of 0 to 10 where 0 is no pain and 10 is the worst pain you can imagine?"  (
         <a class="graphic graphic_figure graphicRef72905" href="/z/d/graphic/72905.html" rel="external">
          figure 2
         </a>
         )). The classification of pain as mild, moderate, or severe using verbal or visual analog rating scales is arbitrary. Others have used the impact of pain on quality of life measures to propose a classification of pain intensity from bone metastases as mild (pain score of 1 to 5), moderate (pain score 6) or severe (pain score 7 to 10) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Neurologic symptoms are not uncommon in patients with vertebral metastases, causing spinal cord compression or spinal instability. Symptoms of cord compression range from pain to neurologic deficits, including motor weakness and paralysis, sensory deficits, bowel and bladder dysfunction, and ataxia. Typically, the deficits result from soft tissue tumor compressing the spinal cord or cauda equina, rather than the pathologic fracture itself. Soft tissue expansion of bone metastasis and compression fracture may also cause nerve root impingement, leading to radiculopathy and pain. (See
         <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">
          "Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma", section on 'Clinical presentation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">
          "Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma", section on 'Assessing spinal stability'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2819.html" rel="external">
          "Clinical features and diagnosis of neoplastic epidural spinal cord compression", section on 'Clinical features'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2002101208">
         <span class="h2">
          Distribution
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, metastatic disease to the bone predominantly involves areas of red marrow, such as the skull, axial skeleton, or the medullary portion of the appendicular skeleton. Less commonly, metastases can be cortically-based surface lesions, although this almost always occurs in the appendicular, rather than the axial, skeleton [
         <a href="#rid17">
          17,18
         </a>
         ]. The most common locations for metastatic disease are the vertebral column, sacrum, pelvis, and proximal femurs [
         <a href="#rid19">
          19-21
         </a>
         ]. Within the spine, the lumbar segment is most frequently involved, followed by the thoracic and cervical segments.
        </p>
        <p>
         The distribution of bone metastases may also be influenced by the specific type of primary malignancy. As an example, metastatic disease is distinctly unusual in anatomic sites distal to the elbow in the upper extremity and distal to the knee in the lower extremity (termed acrometastasis). When bone lesions in these locations are found to be due to metastatic carcinoma, lung and renal cell cancers are the most common primary sites [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13163473">
         <span class="h1">
          DETECTION AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Detection of bone metastases is essential for accurate staging and optimal treatment. The goals of imaging are to identify sites of metastasis and to evaluate individual involved sites for the presence of, or the potential for, pathologic fracture and/or spinal cord compression. Imaging is also used to guide a biopsy, if deemed necessary. (See
         <a class="local">
          'Diagnostic biopsy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3396622">
         <span class="h2">
          Overview of the diagnostic approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no consensus or universal standard approach for detection of osseous metastases in patients with cancer. The choice of imaging should be guided by the clinical presentation and the underlying histologic type of tumor since osteoblastic versus osteolytic patterns vary  (
         <a class="graphic graphic_table graphicRef54124" href="/z/d/graphic/54124.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         When a patient has a known malignancy and presents with progressive bone pain, focused imaging is indicated:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For extremity lesions, radiographs of the affected area are recommended for initial evaluation. If there is no apparent lesion on radiograph, but the clinical suspicion is high then computed tomography (CT) or magnetic resonance imaging (MRI) should be done. Intravenous contrast is not required with either modality but could be helpful in MRI to evaluate for extraosseous soft tissue extension. Radiographs and cross-sectional imaging can help identify patients at risk for pathologic fracture, while cross-sectional imaging can better characterize disease extent and help with preoperative planning. (See
         <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">
          "Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma", section on 'Radiographic studies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For cancer patients presenting with significant back pain, spinal MRI is indicated, even in the absence of any neurologic signs (ie, changes in sensation, weakness, or bowel or bladder dysfunction), to evaluate bone metastasis as well as to rule out epidural extension of tumor and spinal cord compression. The study should be performed with and without contrast as sequences obtained after intravenous contrast administration can be helpful to evaluate the paraspinal soft tissues and meninges. While evaluation of the extent of epidural disease, acuity of fracture development with potential edema, and metastatic osseous involvement is best evaluated with MRI, structural integrity of the bone is best evaluated with CT. MRI can also help differentiate between metastasis and other causes of back pain such as degenerative changes or infection. (See
         <a class="medical medical_review" href="/z/d/html/2819.html" rel="external">
          "Clinical features and diagnosis of neoplastic epidural spinal cord compression", section on 'Magnetic resonance imaging of the spine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initiation of analgesic therapy is indicated to alleviate pain before the etiology is determined while testing is planned or underway. (See
         <a class="medical medical_review" href="/z/d/html/2804.html" rel="external">
          "Overview of cancer pain syndromes", section on 'Multifocal bone pain'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2814.html" rel="external">
          "Cancer pain management with opioids: Optimizing analgesia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2815.html" rel="external">
          "Cancer pain management: Role of adjuvant analgesics (coanalgesics)", section on 'Patients with bone pain'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         While analgesia is being addressed, additional skeletal imaging for further evaluation of bone metastasis can proceed. Our suggested approach to comprehensive skeletal evaluation is outlined in the table; the choice of technetium-99m (Tc-99m) skeletal scintigraphy (ie, bone scan), CT, MRI, 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) integrated with CT (FDG-PET/CT), or a combination of these imaging modalities depends on clinical presentation and/or primary cancer histology for those with a known cancer diagnosis who present with bone pain  (
         <a class="graphic graphic_table graphicRef97119" href="/z/d/graphic/97119.html" rel="external">
          table 2
         </a>
         ). However, in the situation where the patient needs emergent surgical evaluation for oncological emergency or complication (eg, symptomatic epidural spinal cord compression, spinal instability, or pathologic fracture of a weight-bearing bone with severe pain), comprehensive skeletal evaluation or staging workup may be deferred to allow prompt focused evaluation of the painful site followed by urgent intervention.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The need for biopsy depends on whether surgery will be performed, whether clinical diagnosis using imaging evaluation is sufficient, and whether pathological diagnosis is required to confirm metastasis. For patients with no history of cancer, biopsy of skeletal abnormality may be necessary for pathologic diagnosis. For patients whose cancer is in remission, documentation of a pathologic diagnosis may be necessary especially if this is the first evidence of recurrence or disease progression. For patients with known history of stage IV malignancy or who are found to have other visceral metastasis on staging or restaging evaluation, clinical diagnosis with one or more imaging modalities may be sufficient to make a presumptive diagnosis of bone metastasis.
        </p>
        <p>
        </p>
        <p>
         A stepwise approach to diagnosis and evaluation of osseous metastases in patients presenting with nonvertebral bone pain is outlined in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef104784" href="/z/d/graphic/104784.html" rel="external">
          algorithm 1
         </a>
         ); a separate algorithmic approach to diagnostic imaging is presented for patients with back pain  (
         <a class="graphic graphic_algorithm graphicRef104764" href="/z/d/graphic/104764.html" rel="external">
          algorithm 2
         </a>
         ).
        </p>
        <p>
         In general, for most patients with a known cancer capable of mixed lytic and blastic metastasis or pure blastic metastases  (
         <a class="graphic graphic_table graphicRef54124" href="/z/d/graphic/54124.html" rel="external">
          table 1
         </a>
         ), skeletal scintigraphy (bone scan) is indicated. For pure lytic tumors, such as multiple myeloma, a radiographic skeletal survey or whole body cross-sectional imaging (CT or MRI) is indicated to screen the skeleton. For patients with primarily lytic tumors, including metastatic Ewing sarcoma family of tumors (EFT), FDG-PET/CT is the recommended initial step. For patients with sclerotic multiple myeloma (the POEMS syndrome), as well as EFT with a sclerotic primary tumor and for all other patients with suspected bone metastases, bone scan is recommended. Integrated FDG-PET/CT may be the optimal diagnostic study for many solid tumors, especially if the purpose of imaging is to comprehensively evaluate both osseous and nonosseous metastases for the purpose of staging and/or re-staging. These recommendations are in keeping with the consensus-based guidelines of the NCCN [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7744.html" rel="external">
          "Clinical presentation, staging, and prognostic factors of Ewing sarcoma", section on 'Metastatic work-up'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Skeletal surveys'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6662.html" rel="external">
          "POEMS syndrome", section on 'Osteosclerotic bone lesions'
         </a>
         .)
        </p>
        <p>
         Evaluation of a patient with no, or a remote, history of cancer is more complex and must include a search for the primary site; contrast-enhanced CT of the chest, abdomen, and pelvis tailored for visceral organ evaluation plus a bone scan or FDG-PET/CT may be used for comprehensive staging evaluation. In general, diagnostic evaluation should precede biopsy of suspicious bone lesions, particularly if a pathologic or impending pathologic fracture is present or suspected. If primary bone sarcoma is suspected, consultation with an orthopedic oncologist should be obtained, especially prior to biopsy so that the trajectory can be determined. However, if urgent surgical stabilization is needed, and the lesion is unlikely to represent a primary bone sarcoma, a more focused diagnostic evaluation can be performed, and tissue can be removed at the time of surgery to render a pathologic diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/7741.html" rel="external">
          "Bone tumors: Diagnosis and biopsy techniques", section on 'Planning the biopsy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">
          "Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma", section on 'Patients with a remote or no history of cancer'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13163481">
         <span class="h2">
          Specific imaging studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Metastatic bone lesions can present with any radiographic appearance (lytic, blastic, or mixed), regardless of tumor type. However, there are some features that are typical of specific tumors  (
         <a class="graphic graphic_table graphicRef54124" href="/z/d/graphic/54124.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef86427" href="/z/d/graphic/86427.html" rel="external">
          image 1
         </a>
         ); these features may help in selecting appropriate imaging studies and facilitating radiographic interpretation of the abnormalities:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Osteoblastic lesions are typically seen in prostate cancer  (
         <a class="graphic graphic_diagnosticimage graphicRef83139" href="/z/d/graphic/83139.html" rel="external">
          image 2
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Metastases of lung, kidney, and thyroid cancers and bone involvement from multiple myeloma is almost always lytic  (
         <a class="graphic graphic_diagnosticimage graphicRef78569" href="/z/d/graphic/78569.html" rel="external">
          image 3
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mixed lesions are frequently seen in breast cancer
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2002101453">
         <span class="h3">
          Radiographs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radiographs are commonly used as an initial screen to evaluate symptomatic areas and to confirm findings seen with other imaging modalities. Because of poor sensitivity (44 to 50 percent [
         <a href="#rid25">
          25,26
         </a>
         ]), workup for bone metastases cannot end with negative radiographs if the pretest probability of metastasis is high. Spine radiographs may be used to determine the mechanical alignment of the vertebrae and to evaluate for severe compression fracture. Patients with suspected mechanical instability should be urgently referred to a neurosurgeon. In some cases, radiographic skeletal surveys are still used as initial staging in multiple myeloma, although whole body CT and MRI are becoming favored modalities. (See
         <a class="local">
          'Skeletal survey'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Skeletal surveys'
         </a>
         .)
        </p>
        <p>
         Bone lesions on radiographs may appear as areas of faint or absent density (reflecting osteolysis), as disrupted or absent trabecular structure, or as sclerotic lesions or rims. The limited contrast in trabecular bone makes radiographic detection more difficult than for lesions in cortical bone [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         The typical radiographic appearance of a lytic metastasis is a permeative lesion of the diaphysis or metadiaphysis of a proximal long bone or bone of the axial skeleton  (
         <a class="graphic graphic_diagnosticimage graphicRef93404" href="/z/d/graphic/93404.html" rel="external">
          image 4
         </a>
         ). Osteoblastic lesions are usually sclerotic in appearance, sometimes admixed with lytic elements  (
         <a class="graphic graphic_diagnosticimage graphicRef86427" href="/z/d/graphic/86427.html" rel="external">
          image 1
         </a>
         ). In either case, a pathologic fracture line may be visible, and the normal anatomic alignment may be displaced  (
         <a class="graphic graphic_diagnosticimage graphicRef83214" href="/z/d/graphic/83214.html" rel="external">
          image 5
         </a>
         ).
        </p>
        <p>
         Radiographs may also be useful to assess the extent of cortical compromise and the risk of pathologic fracture in a tubular bone. The extent of cortical compromise seen on radiography is an important indicator of the risk of a pathologic fracture in tubular bones  (
         <a class="graphic graphic_table graphicRef90456" href="/z/d/graphic/90456.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">
          "Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma", section on 'Long bones'
         </a>
         .)
        </p>
        <p>
         Compression fractures in vertebral bodies lead to a collapse of the endplates  (
         <a class="graphic graphic_diagnosticimage graphicRef83026" href="/z/d/graphic/83026.html" rel="external">
          image 6
         </a>
         ). However, it may be difficult to distinguish vertebral collapse related to tumor from osteoporotic vertebral collapse on radiographs; MRI may be needed. (See
         <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">
          "Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma", section on 'Cross-sectional imaging'
         </a>
         .)
        </p>
        <p>
         In general, radiographs are more specific, but less sensitive, for bone metastases than bone scan or FDG-PET scan [
         <a href="#rid27">
          27,28
         </a>
         ]. Considerable bone destruction (an estimated 30 to 75 percent reduction in bone density) must be present before a lesion is evident on radiographs [
         <a href="#rid29">
          29
         </a>
         ]. One exception is that radiographs are more sensitive than bone scan for purely lytic metastases (eg, multiple myeloma, some renal cell metastases). (See
         <a class="local">
          'Bone scan'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Imaging'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2002102388">
         <span class="h3">
          Computed tomography or magnetic resonance imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         CT or MRI of the body part of concern may be required to evaluate the following: suspected complete or impending pathologic fractures; suspected epidural spinal cord or cauda equina compression; metastatic bone disease involving the shoulder, spine, or pelvis because of the complex anatomy; or a strong clinical suspicion of bone metastases when other imaging exams are equivocal [
         <a href="#rid30">
          30
         </a>
         ]. Exams to evaluate the entire skeleton for metastasis (ie, whole-body low-dose CT and MRI) are discussed below. (See
         <a class="local">
          'Low-dose, whole-body computed tomography'
         </a>
         below and
         <a class="local">
          'Whole-body magnetic resonance imaging'
         </a>
         below.)
        </p>
        <p>
         Choice of modality is tailored to anatomic site of concern and clinical indication [
         <a href="#rid31">
          31
         </a>
         ]. However, in general, MRI can better evaluate the bone marrow and adjacent soft tissues, while CT can still be helpful in treatment planning. CT is usually performed without intravenous contrast. MRI can also be performed without intravenous contrast; however, postcontrast images can help evaluate extraosseous tumor extension into the adjacent soft tissues.
        </p>
        <p>
         CT is used to diagnose bone metastases if MRI is contraindicated (eg, MRI incompatible pacemaker), or the site of concern is included in a CT obtained to evaluate for extraosseous metastases (eg, torso CT). To assess the integrity of the bone cortex at a site with a known bone metastasis, CT is preferred.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CT demonstrates superior bony detail compared with radiographs and can detect osteolytic and osteoblastic metastases within the bone marrow before there is destruction sufficient to become evident on radiography  (
         <a class="graphic graphic_diagnosticimage graphicRef83492" href="/z/d/graphic/83492.html" rel="external">
          image 7
         </a>
         ) [
         <a href="#rid32">
          32,33
         </a>
         ]. When compared with bone scan, CT demonstrates similar sensitivity. In a meta-analysis of various imaging modalities for the diagnosis of bone metastases in a variety of malignancies, on a per-lesion basis, the sensitivity and specificity of CT were 77 and 83 percent; the corresponding values for bone scan were 75 and 94 percent, respectively [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CT enables high-resolution visualization of the bone cortex. This can aid in the diagnosis of a complete pathologic fracture and in the assessment of fracture risk using newer technology, such as CT-based structural rigidity analysis. (See
         <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">
          "Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma", section on 'CT-based structural rigidity analysis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other benefits from CT compared with radiography are that it shows associated soft tissue disease and provides three-dimensional reconstruction of images, which is helpful for planning radiotherapy (RT) or surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CT involves faster image acquisition than MRI and may be more readily available. However, the soft tissue contrast of CT is inferior to MRI. Therefore, if spinal cord compression, nerve impingement, or adjacent muscle or joint involvement is suspected, MRI should be used.
        </p>
        <p>
        </p>
        <p>
         On the other hand, MRI is more sensitive than CT to detect metastases, allows better delineation of the extent of tumor, and is particularly useful for patients with spine metastases to evaluate the extent of medullary and extraspinal disease. MRI may distinguish benign from malignant compression fractures [
         <a href="#rid27">
          27,33-42
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MRI demonstrates greater accuracy than CT or bone scan and comparable accuracy to FDG-PET/CT in diagnosis of skeletal metastases [
         <a href="#rid34">
          34
         </a>
         ]. On a per-lesion basis, the sensitivity and specificity of MRI, FDG-PET/CT, CT, and bone scan are 91 and 96 percent, 94 and 97 percent, 75 and 94 percent, and 77 and 83 percent, respectively. To specifically evaluate the spine for metastases, MRI is the most accurate modality [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Standard MRI protocols for evaluation of bone metastasis include T1- and T2-weighted imaging without contrast and, often times, postcontrast images. Normal bone marrow usually contains a high percentage of fat and has high signal intensity on T1-weighted images (that do not have fat-saturation). Metastatic lesions display decreased signal on T1-weighted sequences, reflecting the replacement of normal fatty marrow with water-containing tumor; conversely, on T2-weighted images, metastases usually have a higher signal than surrounding normal bone marrow. Metastases usually enhance avidly with contrast in comparison with the surrounding normal tissue.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MRI with and without contrast should be used when spinal cord compression and/or epidural disease/nerve root impingement is suspected because of the excellent soft tissue resolution. It also shows the presence of spinal cord edema and other abnormalities in the spinal cord. (See
         <a class="medical medical_review" href="/z/d/html/2819.html" rel="external">
          "Clinical features and diagnosis of neoplastic epidural spinal cord compression", section on 'Imaging protocol and timing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         MRI can be used to help distinguish a pathologic fracture from an insufficiency fracture by evaluating for an underlying bone marrow replacing lesion [
         <a href="#rid43">
          43
         </a>
         ]. This is particularly relevant in the spine and pelvis, both common locations for insufficiency fractures and metastatic disease. The most common discriminating feature of a pathologic fracture is a well-defined, low-signal T1-weighted abnormality around the fracture, indicating an underlying tumor [
         <a href="#rid44">
          44
         </a>
         ]. Diffusion-weighted imaging with measurement of the apparent diffusion coefficient of the marrow at the fracture site is highly accurate in discriminating benign from pathologic fractures (sensitivity and specificity &gt;90 percent for both) and is often added to conventional imaging [
         <a href="#rid45">
          45,46
         </a>
         ]. However, the added value of this technique has not yet been demonstrated. (See
         <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">
          "Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma", section on 'Cross-sectional imaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Particularly among patients with multiple myeloma, MRI is the gold-standard method for assessing bone marrow infiltration of the spine, predicting the risk of vertebral fracture, and distinguishing benign versus malignant etiologies [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">
          "Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma", section on 'PET/CT plus MRI'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'CT, MRI, and PET'
         </a>
         .)
        </p>
        <p>
         MRI is sensitive to movement and artifact due to metallic objects, which may obscure evaluation. In addition, patients with implantable devices may not be able to undergo MRI. Patients with severe claustrophobia also may not tolerate this study unless it is performed using conscious sedation or, in patients who are not candidates for conscious sedation, under general anesthesia.
        </p>
        <p class="headingAnchor" id="H270468250">
         <span class="h3">
          Whole-body skeletal evaluation
         </span>
        </p>
        <p class="headingAnchor" id="H3396752">
         <span class="h4">
          Bone scan
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tc-99m skeletal scintigraphy, generally referred to as a "bone scan," is the most widely used method to detect bone metastases because it provides visualization of the entire skeleton within a reasonable timeframe and at a reasonable cost. 99m-Tc-methylene diphosphonate (
         <sup>
          99m
         </sup>
         Tc-MDP) is the most commonly used tracer. It accumulates in areas of increased osteoblastic activity, provides a total skeletal examination, and is reliable for detecting metastases in diseases like prostate and breast cancers  (
         <a class="graphic graphic_diagnosticimage graphicRef80098" href="/z/d/graphic/80098.html" rel="external">
          image 8
         </a>
         ).
        </p>
        <p>
         Among patients with a variety of malignancies, including breast, lung, and prostate cancer, bone scan is reasonably sensitive (79 to 86 percent) and specific (81 to 88 percent) for the diagnosis of bone metastases [
         <a href="#rid34">
          34,48,49
         </a>
         ]. However, bone scan is less sensitive for detecting tumors with little to no osteoblastic activity (such as multiple myeloma) and for aggressive lesions with rapid bone destruction because it detects osteoblastic activity resulting in new bone formation. Bone lesions associated with multiple myeloma are only "hot" on bone scan in approximately 20 percent of cases. Lytic lesions can be detected as "cold spots" on bone scan, but these subtle findings may be overlooked.
        </p>
        <p>
         The addition of single-photon tomography (SPECT) to bone scan improves the diagnostic accuracy over bone scan alone but does not improve sensitivity for purely lytic lesions; it is not routinely used [
         <a href="#rid34">
          34,50-54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H355093521">
         <span class="h4">
          Skeletal survey
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of poor sensitivity, skeletal survey radiographs are uncommonly used in screening for bone metastases. While they have typically been used in workup of patients with plasma cell dyscrasias, low dose whole-body CT and MRI are becoming more favored modalities. (See
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Skeletal surveys'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3396789">
         <span class="h4">
          Positron emission tomography (PET) scanning
         </span>
         <span class="headingEndMark">
          —
         </span>
         Metabolic imaging with FDG-PET, without or with integrated CT, has high sensitivity and specificity for diagnosis of distant metastases, including the bone. Integrated FDG-PET/CT is increasingly utilized in clinical staging and restaging evaluation for metastatic disease, including osseous metastasis from solid tumors and multiple myeloma.
        </p>
        <p>
         For some malignancies (ie, lung and breast cancer), FDG-PET is more specific than bone scans for detection of bone metastases, although it is possibly less sensitive (especially for osteoblastic foci) and clearly more expensive [
         <a href="#rid55">
          55-63
         </a>
         ]. As an example, in a meta-analysis of 13 studies directly comparing FDG-PET versus bone scan for detection of bone metastases in patients with breast cancer, the following was found [
         <a href="#rid64">
          64
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         On a per-patient basis, the pooled sensitivity and specificity rates for FDG-PET were 53 and 100 percent; the corresponding values for bone scan were 88 and 96 percent, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         On a per-lesion basis, pooled sensitivity and specificity rates for FDG-PET were 83 and 95 percent; the corresponding values for bone scan were 87 and 88 percent, respectively.
        </p>
        <p>
        </p>
        <p>
         The addition of integrated FDG-PET/CT may improve sensitivity and is a major evaluation tool for cancer staging:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 29 consecutive women with newly diagnosed breast cancer who underwent both integrated FDG-PET/CT and bone scan, the sensitivity and specificity rates for FDG-PET/CT on a per-lesion basis were 96 and 92 percent, while the corresponding values for bone scan were 76 and 95 percent, respectively [
         <a href="#rid65">
          65
         </a>
         ]. For the 16 lesions without a CT correlate, the sensitivity of FDG-PET was only 77 percent. The majority of bone metastases were mixed osteolytic/osteoblastic (48 of 70 or 69 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a meta-analysis of 17 articles comparing integrated FDG-PET/CT, FDG-PET alone, MRI, and bone scan for diagnosis of bone metastases in patients with lung cancer, the per-patient pooled sensitivity and specificity rates for FDG-PET/CT were 92 and 98 percent, respectively; the corresponding rates for FDG-PET alone were 87 and 94 percent, while for bone scan, they were 86 and 88 percent, respectively [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         A major benefit of FDG-PET over bone scan is its ability to screen for distant metastases at sites other than bone [
         <a href="#rid66">
          66,67
         </a>
         ]. Because of this, consensus-based guidelines from the NCCN recommend integrated FDG-PET/CT to evaluate for distant metastases at all sites, including bone, for patients with newly diagnosed non-small cell and small cell lung cancer [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4632.html" rel="external">
          "Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer", section on 'Suggested approaches to diagnostic evaluation and radiographic staging'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4628.html" rel="external">
          "Pathobiology and staging of small cell carcinoma of the lung", section on 'Staging workup'
         </a>
         .)
        </p>
        <p>
         Integrated FDG-PET/CT may also be useful for assessing the whole skeleton in those patients with metastatic thyroid cancer, where the propensity for purely lytic bone metastases renders the bone scan insensitive  (
         <a class="graphic graphic_table graphicRef54124" href="/z/d/graphic/54124.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef86427" href="/z/d/graphic/86427.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef83492" href="/z/d/graphic/83492.html" rel="external">
          image 7
         </a>
         ), and possibly in renal cell and head and neck cancer, in which lytic bone metastases predominate [
         <a href="#rid68">
          68,69
         </a>
         ]. NCCN consensus-based guidelines suggest that integrated PET/CT be considered for the staging of patients with anaplastic thyroid cancer, as well as to evaluate potential distant metastases from a variety of primary head and neck cancer sites, but continue to recommend bone scan as a screen for metastatic osseous disease in renal cell cancer [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3393.html" rel="external">
          "Overview of the diagnosis and staging of head and neck cancer", section on 'Evaluation for distant metastases'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2983.html" rel="external">
          "Clinical manifestations, evaluation, and staging of renal cell carcinoma", section on 'Staging studies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2189.html" rel="external">
          "Anaplastic thyroid cancer", section on 'Imaging'
         </a>
         .)
        </p>
        <p>
         Because of the overall lower incidence of lytic bone metastasis in patients with breast and prostate cancer, bone scan remains the standard diagnostic study in these patients.
        </p>
        <p>
         Other settings where integrated FDG-PET/CT may be preferred over bone scan range from multiple myeloma with a single site of bone involvement or smoldering myeloma, rapidly progressive metastases that are associated with minimal reactive bone formation [
         <a href="#rid70">
          70
         </a>
         ] for the staging of lymphomas that are routinely avid for radiolabeled glucose (eg, diffuse large B cell lymphoma, Hodgkin lymphoma  (
         <a class="graphic graphic_diagnosticimage graphicRef88299" href="/z/d/graphic/88299.html" rel="external">
          image 9
         </a>
         )), and for staging the bone in Ewing sarcoma with a lytic primary tumor. (See
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Imaging'
         </a>
         .)
        </p>
        <p>
         Integrated PET/CT scanning may be of particular utility in differentiating benign versus malignant fractures, particularly in patients with multiple myeloma, in whom the nature of the spine fracture may be more difficult to determine due to the presence of concomitant osteoporosis. (See
         <a class="medical medical_review" href="/z/d/html/7744.html" rel="external">
          "Clinical presentation, staging, and prognostic factors of Ewing sarcoma", section on 'Metastatic work-up'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4696.html" rel="external">
          "Pretreatment evaluation and staging of non-Hodgkin lymphomas", section on 'Positron emission tomography (PET)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">
          "Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma", section on 'PET scan'
         </a>
         .)
        </p>
        <p>
         In addition to FDG-PET/CT, there is growing evidence that integrated PET/CT scanning using 18-fluorine sodium fluoride (NaF PET/CT) may offer increased sensitivity and specificity in evaluating metastatic bone disease compared with Tc-99m-based bone scan in a wide variety of clinical settings [
         <a href="#rid71">
          71-80
         </a>
         ]. NaF is a bone-targeting agent for evaluating osseous metastasis, approved by the US Food and Drug Administration (FDA) as a tracer agent for bone scintigraphy to define areas of osteoblastic activity, independent of cancer type. NaF PET/CT has improved image quality compared with Tc-99 bone scan; a meta-analysis showed sensitivity and specificity of 96.2 and 98.5 percent, respectively, compared with 57 and 98 percent for Tc-99 bone scan [
         <a href="#rid81">
          81
         </a>
         ]. While the use of F-18 NaF PET/CT has been increasing in clinical practice, there are only limited data suggesting clinical superiority over FDG-PET/CT. However, NCCN guidelines endorse NaF PET/CT as an option if there are equivocal results on bone scan for men with unfavorable intermediate-risk, high-risk, very high-risk prostate cancer and women with advanced breast cancer [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/744.html" rel="external">
          "Clinical features, diagnosis, and staging of newly diagnosed breast cancer", section on 'Assessing the extent of local disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16992.html" rel="external">
          "Initial staging and evaluation of males with newly diagnosed prostate cancer", section on 'PET imaging using PSMA-based radiotracers'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="108440" href="/z/d/drug information/108440.html" rel="external">
          Gallium Ga-68 DOTATATE
         </a>
         PET/CT is somatostatin-receptor-based imaging and may be considered for staging evaluation for metastatic workup including bone metastasis for pheochromocytoma, medullary carcinoma, and neuroendocrine tumors [
         <a href="#rid82">
          82
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2194.html" rel="external">
          "Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring", section on 'Somatostatin receptor-based imaging techniques'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2612.html" rel="external">
          "Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms", section on 'Somatostatin-receptor-based imaging'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7848.html" rel="external">
          "Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging", section on 'Radiologic evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/130.html" rel="external">
          "Clinical presentation and diagnosis of pheochromocytoma", section on '68-Ga DOTATATE PET'
         </a>
         .)
        </p>
        <p>
         Prostate-specific membrane antigen (PSMA)-PET tracers are the radiopharmaceuticals that target PSMA on the surface of prostate cells. The FDA has approved F-18 piflufolastat (F-18 DCFPyL),
         <a class="drug drug_general" data-topicid="141714" href="/z/d/drug information/141714.html" rel="external">
          flotufolastat F-18
         </a>
         , and Ga-68 PSMA-11 as the PSMA-PET tracers for prostate cancer imaging. Given the increased sensitivity and specificity of PSMA-PET tracers for detecting micrometastatic disease, the updated NCCN guidelines now recommend PSMA PET/CT, as an alternative to standard imaging of bone and visceral metastasis from prostate cancer for initial staging and at the time of PSA progression. (See
         <a class="medical medical_review" href="/z/d/html/16992.html" rel="external">
          "Initial staging and evaluation of males with newly diagnosed prostate cancer", section on 'PET imaging using PSMA-based radiotracers'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6929.html" rel="external">
          "Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation", section on 'Ga-68 and F-18 PSMA PET/CT'
         </a>
         .)
        </p>
        <p>
         Additional radiopharmaceuticals that are designed to image tumor antigen expression, angiogenesis, and amino acid transport are also being tested for PET applications and may have a future role in those tumor types that are hypometabolic (eg, prostate cancer) and, thus, are not optimally imaged with the current standard FDG-PET/CT [
         <a href="#rid49">
          49,83-85
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H355094752">
         <span class="h4">
          Low-dose, whole-body computed tomography
         </span>
         <span class="headingEndMark">
          —
         </span>
         As a screening test for bone metastases in patients with solid tumors, CT has lower sensitivity than bone scan, whole-body MRI, and FDG-PET for detection of skeletal metastases [
         <a href="#rid25">
          25,34,86
         </a>
         ]. As an example, in a meta-analysis comparing FDG-PET, CT, whole-body MRI, and bone scan for diagnosis of bone metastases, on a per-patient bases, sensitivity and specificity rates for CT were 73 and 95 percent, respectively; the corresponding rates for bone scan were 86 and 81 percent, while for FDG-PET they were 90 and 97 percent, respectively [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         However, one setting in which whole-body, low-dose CT may have utility is in patients with multiple myeloma as an alternative to skeletal survey [
         <a href="#rid87">
          87-90
         </a>
         ]. A meta-analysis concluded that higher detection rates could be achieved with low-dose multidetector CT (MDCT) compared with whole-body radiography in patients with multiple myeloma [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H270468546">
         <span class="h4">
          Whole-body magnetic resonance imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Whole-body MRI has the potential to detect more destructive bone lesions in the axial skeleton (particularly the spine) than bone scan [
         <a href="#rid39">
          39,92,93
         </a>
         ] or, among patients with multiple myeloma, whole-body radiographs [
         <a href="#rid91">
          91,94-96
         </a>
         ]. However, on a per-patient basis, whole-body MRI is less sensitive and less specific than FDG-PET/CT and less sensitive than bone scan [
         <a href="#rid48">
          48
         </a>
         ]. Furthermore, with the current generation of scanners, whole-body MRI is generally not clinically practical in most centers because it would require over one hour of table time for image acquisition. However, whole-body MRI techniques are rapidly advancing with the potential for faster acquisition times and may replace other means of imaging bones, such as bone scan, in the future [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p>
         In patients with suspected or newly diagnosed myeloma, particularly those with a solitary bone lesion or smoldering myeloma, MRI has become the gold-standard imaging method for early detection of bone marrow involvement (in addition to bone destruction, fracture, and spinal cord/nerve compression) [
         <a href="#rid47">
          47
         </a>
         ]. Where whole-body MRI is not available, MRI of the spine and pelvis can be used as it detects approximately 90 percent of focal lesions. (See
         <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">
          "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'CT, MRI, and PET'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H610058542">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of a lytic bone abnormality includes primary malignant bone tumors, bone metastases from distant primary sites, as well as several benign bone lesions. Radiography, as discussed in the above section, may assist in the differential diagnosis  (
         <a class="graphic graphic_table graphicRef96467" href="/z/d/graphic/96467.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
         Primary malignant bone tumors that may appear as lytic lesions include primary bone sarcoma (osteosarcoma  (
         <a class="graphic graphic_diagnosticimage graphicRef70494" href="/z/d/graphic/70494.html" rel="external">
          image 10
         </a>
         ), chondrosarcoma  (
         <a class="graphic graphic_diagnosticimage graphicRef70323" href="/z/d/graphic/70323.html" rel="external">
          image 11
         </a>
         ), fibrosarcoma, Ewing sarcoma of bone  (
         <a class="graphic graphic_figure graphicRef50795" href="/z/d/graphic/50795.html" rel="external">
          figure 3
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef62643" href="/z/d/graphic/62643.html" rel="external">
          image 12
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef61818" href="/z/d/graphic/61818.html" rel="external">
          image 13
         </a>
         ), solitary plasmacytoma of bone [SPB]  (
         <a class="graphic graphic_diagnosticimage graphicRef98496" href="/z/d/graphic/98496.html" rel="external">
          image 14
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef98497" href="/z/d/graphic/98497.html" rel="external">
          image 15
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef98498" href="/z/d/graphic/98498.html" rel="external">
          image 16
         </a>
         ), and primary lymphoma of bone [PLB]  (
         <a class="graphic graphic_diagnosticimage graphicRef61322" href="/z/d/graphic/61322.html" rel="external">
          image 17
         </a>
         )). Most of these primary bone tumors have a characteristic radiographic appearance, although biopsy is generally needed to establish the histologic diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/7741.html" rel="external">
          "Bone tumors: Diagnosis and biopsy techniques", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p>
         "Benign" bone tumors that can present as lytic lesions  (
         <a class="graphic graphic_table graphicRef96467" href="/z/d/graphic/96467.html" rel="external">
          table 4
         </a>
         ) include hemangioma, various types of cysts, lipomas, eosinophilic granuloma, enchondroma, osteoid osteoma, nonossifying fibroma, and giant cell tumor of bone. (See
         <a class="medical medical_review" href="/z/d/html/6294.html" rel="external">
          "Nonmalignant bone lesions in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7731.html" rel="external">
          "Giant cell tumor of bone"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14916.html" rel="external">
          "Radiologic evaluation of knee tumors in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8385.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis", section on 'Lytic bone lesions'
         </a>
         .)
        </p>
        <p>
         The modified Lodwick-Madewell Grading System is a method to categorize lytic bone lesions into those that have a low, moderate, or high risk for malignancy based upon patterns of bone destruction as seen on radiographs [
         <a href="#rid98">
          98
         </a>
         ]. This system is best applied to lesions of the long bones; it may be difficult to apply to calvarial and/or spine lytic bone lesions. Grade I lesions represent lesions with low risk of malignancy, and include well-defined geographic lesions with a sclerotic rim (IA) and geographic lesions with a sharp margin without a sclerotic rim (IB). Grade II lesions are geographic lesions with ill-defined margins, while grade III lesions include those with a moth-eaten or permeative appearance, indicating a high risk of malignancy.
        </p>
        <p>
         The differential diagnosis of a sclerotic or blastic bone lesion is narrower. A bone island, also known as an enostosis, is a focus of compact bone located in cancellous bone  (
         <a class="graphic graphic_diagnosticimage graphicRef96035" href="/z/d/graphic/96035.html" rel="external">
          image 18
         </a>
         ). This is a benign entity that is usually found, incidentally, on imaging studies that may mimic an osteoblastic metastasis; CT attenuation measurements can aid in the distinction [
         <a href="#rid99">
          99
         </a>
         ]. Other benign conditions that may present as a solitary sclerotic bone lesion are calcifying enchondroma, osteoid osteoma  (
         <a class="graphic graphic_diagnosticimage graphicRef98167" href="/z/d/graphic/98167.html" rel="external">
          image 19
         </a>
         ), bone infarct, fibrous dysplasia, Paget disease of bone, and vertebral venous congestion in patients with thrombosis of the superior vena cava [
         <a href="#rid100">
          100
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5601.html" rel="external">
          "Clinical manifestations and diagnosis of Paget disease of bone"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6294.html" rel="external">
          "Nonmalignant bone lesions in children and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2002101396">
         <span class="h2">
          Diagnostic biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Definitive diagnosis of bone metastasis requires histologic examination of biopsy material. However, tissue diagnosis may not be needed for all patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a primary tumor is known, a skeletal lesion with a typical appearance on imaging studies (either lytic or osteoblastic  (
         <a class="graphic graphic_table graphicRef54124" href="/z/d/graphic/54124.html" rel="external">
          table 1
         </a>
         )) may be presumed to be metastatic, especially if there are multiple lesions and the radiographic appearance is typical. However, because of the dire prognostic implications of metastatic disease, the possibility that the finding could represent a benign lesion (21 percent in one study of 482 patients with a single known primary malignancy who underwent biopsy of a suspicious bone lesion [
         <a href="#rid101">
          101
         </a>
         ]) and the outside possibility of a second occult primary malignancy (estimated to occur in 3 percent of cases in this same study [
         <a href="#rid101">
          101
         </a>
         ]), histologic confirmation of an initial site of bone metastasis is recommended. Of course, it is neither feasible nor desirable to confirm each metastatic lesion by biopsy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If a patient has a history of cancer without prior documentation of bone metastases and a confirmatory diagnosis of metastatic disease is all that is required, needle biopsy can be an excellent method to acquire enough tissue simply to document the presence of metastatic disease. CT-guided fine needle aspiration biopsy (FNA) is easy to perform and accurate in this setting [
         <a href="#rid102">
          102,103
         </a>
         ]. Core biopsy has higher diagnostic accuracy for determining the type, grade, and specific diagnosis of musculoskeletal tumors but may not be needed. An example of a situation in which this would be particularly helpful would be in the case of a patient with a remote estrogen receptor positive (ER+), progesterone receptor positive (PR+), and Her-2-neu positive invasive ductal breast cancer who now presents with bony metastases after a long disease-free interval. Potential hormonal therapy options for bone-only metastatic disease in this setting would be guided by knowing the molecular profile of the metastases. Open biopsy is rarely, if ever, needed. (See
         <a class="medical medical_review" href="/z/d/html/7741.html" rel="external">
          "Bone tumors: Diagnosis and biopsy techniques"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with an unknown primary cancer who present with a bone metastasis, and initial staging evaluation fails to delineate the primary malignancy, a biopsy is generally indicated to both confirm the malignant nature of the bone lesion and to provide histologic information about likely primary sites. Identification of the primary tumor may permit patients to benefit from therapy that is tailored to the specific type of malignancy. However, biopsy of the metastatic deposit may or may not indicate the most likely source of the primary malignancy, even when sophisticated histologic techniques are used [
         <a href="#rid104">
          104,105
         </a>
         ]. In this setting, an FNA biopsy may not provide sufficient information to guide in the evaluation of a possible primary site, and a core biopsy may be needed in order to permit immunohistochemical evaluation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the past, this scenario prompted the performance of elaborate imaging evaluations in an attempt to locate the primary site, but with limited success. It is now recommended that the diagnostic work-up be selectively chosen based upon the history, the patient's sex, the clinical findings, and laboratory tests. The topic of neoplasms of unknown primary site is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4878.html" rel="external">
          "Overview of the classification and management of cancers of unknown primary site"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An impending or complete pathologic fracture in a patient with a solitary bone lesion, with or without a history of cancer, should never be fixed without a tissue diagnosis. Should the lesion prove to be a primary mesenchymal malignancy (eg, osteosarcoma, chondrosarcoma), the surgical repair could jeopardize not only the opportunity for limb salvage, but also the possibility of cure. If the biopsy is to be done in advance by an interventional radiologist, discussion with the physician performing the biopsy is very important as the biopsy should be performed in a location that will permit excision of the biopsy tract should a primary sarcoma be diagnosed. Collaboration with an orthopedic oncologist is advised in this setting. (See
         <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">
          "Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma", section on 'Diagnostic biopsy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H216169520">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114874.html" rel="external">
          "Society guideline links: Neoplastic epidural spinal cord compression"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/119939.html" rel="external">
          "Society guideline links: Management of bone metastases in solid tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3434921739">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/132577.html" rel="external">
          "Patient education: Bone metastases (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H448365904">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical presentation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bone metastases are a common manifestation of distant relapse from many types of solid cancers, especially lung, breast, prostate cancer, and multiple myeloma. Metastatic bone disease is a prominent source of morbidity and a major contributor to deterioration in quality of life. Skeletal-related events (SREs) attributed to bone metastases include pain, pathologic fracture, hypercalcemia, and spinal cord compression. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Most patients with metastatic bone disease will develop significant pain at some point. Neurologic symptoms may arise if spine metastases cause spinal cord compression or spinal instability. Patients with osteolytic bone metastases may also present with hypercalcemia. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic approach
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The goals of imaging are to identify sites of metastasis and to evaluate individual involved sites for the presence of, or potential for, complications such as pathologic fracture and spinal cord compression, and to guide the biopsy, if deemed necessary. (See
         <a class="local">
          'Detection and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The choice of imaging should be guided by the clinical presentation and the underlying histologic tumor type. In general, cross sectional imaging of the affected body part may be required for the evaluation of suspected pathologic fractures; disease extent; suspected epidural spinal cord compression or spinal instability; metastatic bone disease involving the shoulder, spine, or pelvis because of the complex anatomy; or a strong clinical suspicion of bone metastases when other imaging exams are equivocal. Choice of modality (computed tomography [CT], magnetic resonance imaging [MRI]) is tailored to the anatomic site of concern and the clinical indication. MRI is particularly useful for patients with spine metastases to allow evaluation of the extent of medullary and extraspinal disease, and spinal cord and nerve root compression. For suspected or newly diagnosed multiple myeloma, MRI is the gold-standard imaging for skeletal and marrow abnormality. (See
         <a class="local">
          'Computed tomography or magnetic resonance imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Our suggested diagnostic approach is outlined in the algorithms  (
         <a class="graphic graphic_algorithm graphicRef104784" href="/z/d/graphic/104784.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef104764" href="/z/d/graphic/104764.html" rel="external">
          algorithm 2
         </a>
         ), and summarized as follows (see
         <a class="local">
          'Overview of the diagnostic approach'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with a known cancer diagnosis presenting with back pain, spinal MRI without and with contrast is indicated, especially for evaluation of bone metastasis and spinal cord compression  (
         <a class="graphic graphic_algorithm graphicRef104764" href="/z/d/graphic/104764.html" rel="external">
          algorithm 2
         </a>
         ). Postcontrast images are acquired to evaluate for tumor spread into the paraspinal soft tissue. (See
         <a class="medical medical_review" href="/z/d/html/2819.html" rel="external">
          "Clinical features and diagnosis of neoplastic epidural spinal cord compression", section on 'Magnetic resonance imaging of the spine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with nonvertebral bone pain, initial evaluation should include a radiograph of the affected area. If a complete or impending pathologic fracture is suspected, cross-sectional imaging with contrast-enhanced CT or MRI without and with contrast can identify patients who may need surgical stabilization  (
         <a class="graphic graphic_algorithm graphicRef104784" href="/z/d/graphic/104784.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/83811.html" rel="external">
          "Clinical presentation and evaluation of complete and impending pathologic fractures in patients with metastatic bone disease, multiple myeloma, and lymphoma", section on 'Radiographic studies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Subsequent whole-body skeletal evaluation is generally the next step to screen the rest of the skeleton for bone metastases, for both vertebral and nonvertebral metastases. 99m-technetium-methylene diphosphonate skeletal scintigraphy, generally referred to as a "bone scan," is the most widely used method to detect bone metastases because it provides visualization of the entire skeleton within a reasonable timeframe. (See
         <a class="local">
          'Bone scan'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         However, the whole-body radiographic bone survey (typically with low-dose CT or whole body MRI) is preferred for staging of patients with multiple myeloma because of poor sensitivity of bone scan in this situation  (
         <a class="graphic graphic_table graphicRef97119" href="/z/d/graphic/97119.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Radiographs'
         </a>
         above and
         <a class="local">
          'Skeletal survey'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Metabolic imaging with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) integrated with CT (FDG-PET/CT) is often utilized for initial staging of patients with Ewing sarcoma and a lytic primary tumor, and for those with rapidly progressive metastases associated with minimal reactive bone formation. FDG-PET/CT is also commonly used for staging and/or restaging of solid cancers when the goal is to screen for both osseous and nonosseous metastases  (
         <a class="graphic graphic_table graphicRef97119" href="/z/d/graphic/97119.html" rel="external">
          table 2
         </a>
         ). PET/CT using novel PET tracers such as Ga-68 DODATATE for neuroendocrine tumors or Ga-68 PSMA-11 for prostate cancer are increasingly used as an alternative to standard imaging. (See
         <a class="local">
          'Positron emission tomography (PET) scanning'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Differential diagnosis of metastatic bone disease includes primary bone sarcomas (osteosarcoma, chondrosarcoma, fibrosarcoma, and Ewing sarcoma of bone), solitary plasmacytoma of bone (SPB), and primary lymphoma of bone (PLB). Benign bone tumors that can present as lytic lesions include hemangioma, various types of cysts, lipomas, eosinophilic granuloma, enchondroma, nonossifying fibroma, and giant cell tumor of bone. Benign conditions that may present as a solitary sclerotic bone lesion include a bone island (enostosis), calcifying enchondroma, osteoid osteoma, bone infarct, fibrous dysplasia, and Paget disease of bone. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Definitive diagnosis of bone metastases requires histologic examination of biopsy material. However, tissue diagnosis may not be needed for all patients. If a patient has a history of cancer without prior documentation of bone metastases and a confirmatory diagnosis of metastatic disease is all that is required, needle biopsy is an appropriate choice. (See
         <a class="local">
          'Diagnostic biopsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1131289390">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Thomas F DeLaney, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12:6243s.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pockett RD, Castellano D, McEwan P, et al. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl) 2010; 19:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theriault RL, Theriault RL. Biology of bone metastases. Cancer Control 2012; 19:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen OS. Palliative radiotherapy of bone metastases: there is now evidence for the use of single fractions. Radiother Oncol 1999; 52:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eastley N, Newey M, Ashford RU. Skeletal metastases - the role of the orthopaedic and spinal surgeon. Surg Oncol 2012; 21:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bubendorf L, Schöpfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 1983; 23:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dispenzieri A. POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014; 89:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110:973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan CJ, Elkin EP, Cowan J, Carroll PR. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE. Cancer 2007; 110:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker MS, Miller PJ, Namjoshi M, et al. Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases. J Med Econ 2013; 16:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brodowicz T, O'Byrne K, Manegold C. Bone matters in lung cancer. Ann Oncol 2012; 23:2215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer 2007; 109:2334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svendsen ML, Gammelager H, Sværke C, et al. Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark. Clin Epidemiol 2013; 5:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald R, Ding K, Chow E, et al. Classification of painful bone metastases as mild, moderate, or severe using both EORTC QLQ-C15-PAL and EORTC QLQ-BM22. Support Care Cancer 2016; 24:4871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miric A, Banks M, Allen D, et al. Cortical metastatic lesions of the appendicular skeleton from tumors of known primary origin. J Surg Oncol 1998; 67:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenspan A, Norman A. Osteolytic cortical destruction: an unusual pattern of skeletal metastases. Skeletal Radiol 1988; 17:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi J, Raghavan M. Diagnostic imaging and image-guided therapy of skeletal metastases. Cancer Control 2012; 19:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krishnamurthy GT, Tubis M, Hiss J, Blahd WH. Distribution pattern of metastatic bone disease. A need for total body skeletal image. JAMA 1977; 237:2504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tubiana-Hulin M. Incidence, prevalence and distribution of bone metastases. Bone 1991; 12 Suppl 1:S9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borgohain B, Borgohain N, Khonglah T, Bareh J. Occult renal cell carcinoma with acrometastasis and ipsilateral juxta-articular knee lesions mimicking acute inflammation. Adv Biomed Res 2012; 1:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koyama M, Koizumi M. FDG-PET images of acrometastases. Clin Nucl Med 2014; 39:298.
          </a>
         </li>
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muindi J, Coombes RC, Golding S, et al. The role of computed tomography in the detection of bone metastases in breast cancer patients. Br J Radiol 1983; 56:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galasko CS. The value of scintigraphy in malignant disease. Cancer Treat Rev 1975; 2:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol 2004; 22:2942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez DJ, Powles TJ, Milan J, et al. Detection of breast carcinoma metastases in bone: relative merits of X-rays and skeletal scintigraphy. Lancet 1983; 2:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Even-Sapir E. Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities. J Nucl Med 2005; 46:1356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bickels J, Dadia S, Lidar Z. Surgical management of metastatic bone disease. J Bone Joint Surg Am 2009; 91:1503.
          </a>
         </li>
         <li class="breakAll">
          American College of Radiology Appropriateness Criteria. Metastatic bone disease. https://acsearch.acr.org/docs/69431/Narrative/ (Accessed on July 10, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med 2001; 45:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahnken AH, Wildberger JE, Gehbauer G, et al. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR Am J Roentgenol 2002; 178:1429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang HL, Liu T, Wang XM, et al. Diagnosis of bone metastases: a meta-analysis comparing ¹⁸FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 2011; 21:2604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frank JA, Ling A, Patronas NJ, et al. Detection of malignant bone tumors: MR imaging vs scintigraphy. AJR Am J Roentgenol 1990; 155:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003; 290:3199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinborn MM, Heuck AF, Tiling R, et al. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr 1999; 23:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haubold-Reuter BG, Duewell S, Schilcher BR, et al. The value of bone scintigraphy, bone marrow scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumours: a prospective study. Eur J Nucl Med 1993; 20:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001; 177:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Godersky JC, Smoker WR, Knutzon R. Use of magnetic resonance imaging in the evaluation of metastatic spinal disease. Neurosurgery 1987; 21:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baur-Melnyk A, Buhmann S, Becker C, et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol 2008; 190:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu T, Wang S, Liu H, et al. Detection of vertebral metastases: a meta-analysis comparing MRI, CT, PET, BS and BS with SPECT. J Cancer Res Clin Oncol 2017; 143:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fayad LM, Kamel IR, Kawamoto S, et al. Distinguishing stress fractures from pathologic fractures: a multimodality approach. Skeletal Radiol 2005; 34:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuh WT, Zachar CK, Barloon TJ, et al. Vertebral compression fractures: distinction between benign and malignant causes with MR imaging. Radiology 1989; 172:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suh CH, Yun SJ, Jin W, et al. ADC as a useful diagnostic tool for differentiating benign and malignant vertebral bone marrow lesions and compression fractures: a systematic review and meta-analysis. Eur Radiol 2018; 28:2890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo Z, Litao L, Gu S, et al. Standard-b-value vs low-b-value DWI for differentiation of benign and malignant vertebral fractures: a meta-analysis. Br J Radiol 2016; 89:20150384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimopoulos MA, Hillengass J, Usmani S, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol 2015; 33:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qu X, Huang X, Yan W, et al. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol 2012; 81:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol 2014; 43:1503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savelli G, Chiti A, Grasselli G, et al. The role of bone SPET study in diagnosis of single vertebral metastases. Anticancer Res 2000; 20:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savelli G, Maffioli L, Maccauro M, et al. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med 2001; 45:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan PJ, Fogelman I. The bone scan: where are we now? Semin Nucl Med 1995; 25:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roland J, van den Weyngaert D, Krug B, et al. Metastases seen on SPECT imaging despite a normal planar bone scan. Clin Nucl Med 1995; 20:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sedonja I, Budihna NV. The benefit of SPECT when added to planar scintigraphy in patients with bone metastases in the spine. Clin Nucl Med 1999; 24:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kao CH, Hsieh JF, Tsai SC, et al. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 2000; 20:2189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003; 38:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schirrmeister H, Glatting G, Hetzel J, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001; 42:1800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999; 17:2381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook GJ, Fogelman I. The role of positron emission tomography in the management of bone metastases. Cancer 2000; 88:2927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook GJ, Houston S, Rubens R, et al. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16:3375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bury T, Barreto A, Daenen F, et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998; 25:1244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coleman RE. Monitoring of bone metastases. Eur J Cancer 1998; 34:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shie P, Cardarelli R, Brandon D, et al. Meta-analysis: comparison of F-18 Fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med 2008; 33:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu T, Cheng T, Xu W, et al. A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skeletal Radiol 2011; 40:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hahn S, Heusner T, Kümmel S, et al. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. Acta Radiol 2011; 52:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Völker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007; 25:5435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peterson JJ. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors. Semin Musculoskelet Radiol 2007; 11:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Staudenherz A, Steiner B, Puig S, et al. Is there a diagnostic role for bone scanning of patients with a high pretest probability for metastatic renal cell carcinoma? Cancer 1999; 85:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown DH, Leakos M. The value of a routine bone scan in a metastatic survey. J Otolaryngol 1998; 27:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med 2005; 35:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bortot DC, Amorim BJ, Oki GC, et al. ¹⁸F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy. Eur J Nucl Med Mol Imaging 2012; 39:1730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng X, Li Y, Xu Z, et al. Comparison of 18F-FDG PET/CT with bone scintigraphy for detection of bone metastasis: a meta-analysis. Acta Radiol 2011; 52:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang MC, Chen JH, Liang JA, et al. Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer. Acad Radiol 2012; 19:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JW, Lee SM, Lee HS, et al. Comparison of diagnostic ability between (99m)Tc-MDP bone scan and (18)F-FDG PET/CT for bone metastasis in patients with small cell lung cancer. Ann Nucl Med 2012; 26:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rong J, Wang S, Ding Q, et al. Comparison of 18 FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. Surg Oncol 2013; 22:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poulsen MH, Petersen H, Høilund-Carlsen PF, et al. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT. BJU Int 2014; 114:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qiu ZL, Xue YL, Song HJ, Luo QY. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. Nucl Med Commun 2012; 33:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ota N, Kato K, Iwano S, et al. Comparison of ¹⁸F-fluoride PET/CT, ¹⁸F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study. Br J Radiol 2014; 87:20130444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma DW, Kim JH, Jeon TJ, et al. ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography for the evaluation of bone metastasis in patients with gastric cancer. Dig Liver Dis 2013; 45:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Lammeren-Venema D, Regelink JC, Riphagen II, et al. ¹⁸F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. Cancer 2012; 118:1971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tateishi U, Morita S, Taguri M, et al. A meta-analysis of (18)F-Fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med 2010; 24:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanli Y, Garg I, Kandathil A, et al. Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT. AJR Am J Roentgenol 2018; 211:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vallabhajosula S, Solnes L, Vallabhajosula B. A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new? Semin Nucl Med 2011; 41:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Eyben FE, Kairemo K. Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun 2014; 35:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kannivelu A, Loke KS, Kok TY, et al. The role of PET/CT in the evaluation of skeletal metastases. Semin Musculoskelet Radiol 2014; 18:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kido DK, Gould R, Taati F, et al. Comparative sensitivity of CT scans, radiographs and radionuclide bone scans in detecting metastatic calvarial lesions. Radiology 1978; 128:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horger M, Claussen CD, Bross-Bach U, et al. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography. Eur J Radiol 2005; 54:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chassang M, Grimaud A, Cucchi JM, et al. Can low-dose computed tomographic scan of the spine replace conventional radiography? An evaluation based on imaging myelomas, bone metastases, and fractures from osteoporosis. Clin Imaging 2007; 31:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hur J, Yoon CS, Ryu YH, et al. Efficacy of multidetector row computed tomography of the spine in patients with multiple myeloma: comparison with magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography. J Comput Assist Tomogr 2007; 31:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pianko MJ, Terpos E, Roodman GD, et al. Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease. Clin Cancer Res 2014; 20:5888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Regelink JC, Minnema MC, Terpos E, et al. Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review. Br J Haematol 2013; 162:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colletti PM, Dang HT, Deseran MW, et al. Spinal MR imaging in suspected metastases: correlation with skeletal scintigraphy. Magn Reson Imaging 1991; 9:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kattapuram SV, Khurana JS, Scott JA, el-Khoury GY. Negative scintigraphy with positive magnetic resonance imaging in bone metastases. Skeletal Radiol 1990; 19:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dinter DJ, Neff WK, Klaus J, et al. Comparison of whole-body MR imaging and conventional X-ray examination in patients with multiple myeloma and implications for therapy. Ann Hematol 2009; 88:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghanem N, Lohrmann C, Engelhardt M, et al. Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol 2006; 16:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gleeson TG, Moriarty J, Shortt CP, et al. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiol 2009; 38:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauenstein TC, Goehde SC, Herborn CU, et al. Three-dimensional volumetric interpolated breath-hold MR imaging for whole-body tumor staging in less than 15 minutes: a feasibility study. AJR Am J Roentgenol 2002; 179:445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caracciolo JT, Temple HT, Letson GD, Kransdorf MJ. A Modified Lodwick-Madewell Grading System for the Evaluation of Lytic Bone Lesions. AJR Am J Roentgenol 2016; 207:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ulano A, Bredella MA, Burke P, et al. Distinguishing Untreated Osteoblastic Metastases From Enostoses Using CT Attenuation Measurements. AJR Am J Roentgenol 2016; 207:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kara M, Pradel C, Phan C, et al. CT Features of Vertebral Venous Congestion Simulating Sclerotic Metastases in Nine Patients With Thrombosis of the Superior Vena Cava. AJR Am J Roentgenol 2016; 207:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raphael B, Hwang S, Lefkowitz RA, et al. Biopsy of suspicious bone lesions in patients with a single known malignancy: prevalence of a second malignancy. AJR Am J Roentgenol 2013; 201:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monfardini L, Preda L, Aurilio G, et al. CT-guided bone biopsy in cancer patients with suspected bone metastases: retrospective review of 308 procedures. Radiol Med 2014; 119:852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wedin R, Bauer HC, Skoog L, et al. Cytological diagnosis of skeletal lesions. Fine-needle aspiration biopsy in 110 tumours. J Bone Joint Surg Br 2000; 82:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alcalay M, Azais I, Brigeon B, et al. Strategy for identifying primary malignancies with inaugural bone metastases. Rev Rhum Engl Ed 1995; 62:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rougraff BT, Kneisl JS, Simon MA. Skeletal metastases of unknown origin. A prospective study of a diagnostic strategy. J Bone Joint Surg Am 1993; 75:1276.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 91912 Version 40.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12154351" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Metastasis to bone: causes, consequences and therapeutic opportunities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17062708" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinical features of metastatic bone disease and risk of skeletal morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19708928" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22487971" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Biology of bone metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10577693" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Palliative radiotherapy of bone metastases: there is now evidence for the use of single fractions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22554913" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Skeletal metastases - the role of the orthopaedic and spinal surgeon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10836297" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6345937" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Breast carcinoma: pattern of metastasis at autopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24532337" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17647245" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17516446" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23043593" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22357445" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Bone matters in lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17450591" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Economic burden of metastatic bone disease in the U.S.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23576882" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27465049" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Classification of painful bone metastases as mild, moderate, or severe using both EORTC QLQ-C15-PAL and EORTC QLQ-BM22.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9579374" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Cortical metastatic lesions of the appendicular skeleton from tumors of known primary origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3238438" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Osteolytic cortical destruction: an unusual pattern of skeletal metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22487972" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Diagnostic imaging and image-guided therapy of skeletal metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/576963" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Distribution pattern of metastatic bone disease. A need for total body skeletal image.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1954049" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Incidence, prevalence and distribution of bone metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23326779" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Occult renal cell carcinoma with acrometastasis and ipsilateral juxta-articular knee lesions mimicking acute inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24458182" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : FDG-PET images of acrometastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24458182" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : FDG-PET images of acrometastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6831145" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The role of computed tomography in the detection of bone metastases in breast cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/766965" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The value of scintigraphy in malignant disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15254062" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Bone imaging in metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6136757" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Detection of breast carcinoma metastases in bone: relative merits of X-rays and skeletal scintigraphy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16085595" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Imaging of malignant bone involvement by morphologic, scintigraphic, and hybrid modalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19487532" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Surgical management of metastatic bone disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19487532" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Surgical management of metastatic bone disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11456376" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Radiological imaging for the diagnosis of bone metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12034612" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21887484" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Diagnosis of bone metastases: a meta-analysis comparing¹⁸FDG PET, CT, MRI and bone scintigraphy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2120933" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Detection of malignant bone tumors: MR imaging vs scintigraphy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14693872" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10050822" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8287874" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The value of bone scintigraphy, bone marrow scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumours: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11418435" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3696401" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Use of magnetic resonance imaging in the evaluation of metastatic spinal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18356461" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Whole-body MRI versus whole-body MDCT for staging of multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27752772" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Detection of vertebral metastases: a meta-analysis comparing MRI, CT, PET, BS and BS with SPECT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15838703" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Distinguishing stress fractures from pathologic fractures: a multimodality approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2740506" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Vertebral compression fractures: distinction between benign and malignant causes with MR imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29450718" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : ADC as a useful diagnostic tool for differentiating benign and malignant vertebral bone marrow lesions and compression fractures: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26612466" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Standard-b-value vs low-b-value DWI for differentiation of benign and malignant vertebral fractures: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25605835" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21354739" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A meta-analysis of¹⁸FDG-PET-CT,¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24841276" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10810405" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The role of bone SPET study in diagnosis of single vertebral metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11456373" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7597422" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The bone scan: where are we now?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8674288" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Metastases seen on SPECT imaging despite a normal planar bone scan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10361935" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The benefit of SPECT when added to planar scintigraphy in patients with bone metastases in the spine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10928175" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12750613" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11752076" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10561300" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10898336" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The role of positron emission tomography in the management of bone metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9779715" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9724372" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9741329" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Monitoring of bone metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18209527" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Meta-analysis: comparison of F-18 Fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20495798" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21969709" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18048826" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18260035" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9921987" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Is there a diagnostic role for bone scanning of patients with a high pretest probability for metastatic renal cell carcinoma?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9711511" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : The value of a routine bone scan in a metastatic survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15765376" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Positron emission tomography and bone metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22949079" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : ¹⁸F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21712464" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Comparison of 18F-FDG PET/CT with bone scintigraphy for detection of bone metastasis: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22173321" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22729551" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Comparison of diagnostic ability between (99m)Tc-MDP bone scan and (18)F-FDG PET/CT for bone metastasis in patients with small cell lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23726506" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Comparison of 18 FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24314065" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23111353" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24297809" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Comparison of¹⁸F-fluoride PET/CT,¹⁸F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23831128" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography for the evaluation of bone metastasis in patients with gastric cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21887677" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : ¹⁸F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20559896" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : A meta-analysis of (18)F-Fluoride positron emission tomography for assessment of metastatic bone tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29975116" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21624560" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24240194" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24715447" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : The role of PET/CT in the evaluation of skeletal metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/663247" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Comparative sensitivity of CT scans, radiographs and radionuclide bone scans in detecting metastatic calvarial lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15837412" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17599614" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Can low-dose computed tomographic scan of the spine replace conventional radiography? An evaluation based on imaging myelomas, bone metastases, and fractures from osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17538276" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Efficacy of multidetector row computed tomography of the spine in patients with multiple myeloma: comparison with magnetic resonance imaging and fluorodeoxyglucose-positron emission tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25294899" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23617231" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1881253" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Spinal MR imaging in suspected metastases: correlation with skeletal scintigraphy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2321040" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Negative scintigraphy with positive magnetic resonance imaging in bone metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18941746" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Comparison of whole-body MR imaging and conventional X-ray examination in patients with multiple myeloma and implications for therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16463030" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19009290" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12130448" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Three-dimensional volumetric interpolated breath-hold MR imaging for whole-body tumor staging in less than 15 minutes: a feasibility study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27070373" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : A Modified Lodwick-Madewell Grading System for the Evaluation of Lytic Bone Lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27101076" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Distinguishing Untreated Osteoblastic Metastases From Enostoses Using CT Attenuation Measurements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27064458" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : CT Features of Vertebral Venous Congestion Simulating Sclerotic Metastases in Nine Patients With Thrombosis of the Superior Vena Cava.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24261372" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Biopsy of suspicious bone lesions in patients with a single known malignancy: prevalence of a second malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24700152" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : CT-guided bone biopsy in cancer patients with suspected bone metastases: retrospective review of 308 procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10963164" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Cytological diagnosis of skeletal lesions. Fine-needle aspiration biopsy in 110 tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8624672" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Strategy for identifying primary malignancies with inaugural bone metastases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8408149" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Skeletal metastases of unknown origin. A prospective study of a diagnostic strategy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
